Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.
about
Biological response modifiers in cancerRecent clinical studies of the immunomodulatory drug (IMiD) lenalidomideChronic myelomonocytic leukemiaThalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.Treatment options for myelodysplastic syndromes.Immunomodulatory drugs in myelodysplastic syndromes.Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.The role of lenalidomide in the management of myelodysplasia with del 5q.Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)Thalidomide as an anti-cancer agent.Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesThalidomide and its derivatives: emerging from the wilderness.Myelodysplasia--therapeutic response to novel therapy and the need for new diagnostic groups.Thalidomide: a new anticancer drug?A model for the functional assessment of elderly with myeloid neoplasmsArsenic trioxide for the treatment of myelodysplastic syndromes.Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.Thalidomide for the treatment of multiple myeloma.Thalidomide and immunomodulatory drugs in the treatment of cancer.Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis.Dyspnea during thalidomide treatment for advanced ovarian cancer.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Angiogenesis and hematological malignancies.Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes.Emerging drugs for the treatment of myelodysplastic syndrome.Pulmonary toxicity from novel antineoplastic agents.Immunomodulatory drugs.Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.The evolving role of lenalidomide in the treatment of hematologic malignancies.Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes.Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Treatment strategies in myelodysplastic syndromes.Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome.New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?
P2860
Q24685049-B9626727-9761-43D6-92E3-1EC83E254E08Q28192646-AE970641-5B8C-485E-9A53-4EEF417B4903Q28203692-D19FA5E8-6F15-4332-98A1-2D609ABE64DBQ30773458-3D4638A2-5D8D-4AB1-8C13-978F741E8C4DQ33364350-941553B3-96F7-4C59-8669-54C72AA9B53CQ33371622-E304EC88-5ABE-401E-B190-8E5D12D698C1Q33373984-04B6A5FF-980C-43A9-8E91-EF6811A88AE0Q33376920-87F31F34-3794-4D92-B3C0-194006BC98F2Q33378398-C8D2E78A-8A0F-44D7-8AA1-A70B28BBC022Q33379562-B687E492-0DA7-4FEF-9A4B-AA81226BE3D2Q33382047-C8FEFE13-C961-4D4F-B915-3C9DEE055310Q33393647-E734A0D7-70E9-422B-9093-BC705F349C8BQ34560200-E860C06A-5B57-4AFE-B0E1-6DA2D0F5A811Q34778074-AA9B5C29-0F6B-4319-B71F-D414E91CB167Q34783754-5D95CA4F-9CF7-4196-BD2D-E7E4E9F525C3Q35107977-29C69EBC-361F-4E71-ABB1-53B90718424EQ35134995-5B059428-C574-48BE-9437-BD0DD161DC47Q35164773-713A836A-EB8C-40E1-96EE-B99B7098DF4DQ35244361-61615068-95CF-4847-B0FB-FF35C888F477Q35688178-909D5EFD-F2E4-4D28-8B58-92E57F73925AQ35848761-8E9D2AB9-9D2C-43AF-A9B8-26D92B1F48B5Q35870500-BB990842-FFB8-482F-BEB4-40481AEC5162Q36040871-30F024CD-35CB-4C0C-AF2C-8A71082D64ACQ36059602-F4A931FE-E3C2-49C1-B949-4611F5402698Q36089929-0B927576-C647-46CA-BCB8-7E8D5EF69804Q36171864-E28DC875-84CA-42BD-B1BA-7900E76ABB6AQ36194525-C44D3744-66B5-45C0-B04C-D443C8F202FFQ36194610-C5E2719D-AF9F-4E05-A223-DC6EE18488ACQ36219655-97C8AC8A-191E-4FDA-90B3-5F6F8087C01CQ36314452-94D697DB-EBC0-4CE6-A7CE-C12BC87EC5E0Q36321396-58C45C99-394E-420D-9546-3A3FEB6CD3FAQ36364976-6446BA55-D667-4201-AB33-1E05ECE9B9D5Q36739807-3ABA36F5-38D7-42FB-BF71-947AF758F148Q36773010-1A629E0B-C101-4F77-84CD-C4FE1B433108Q36814964-09CB6526-6C5B-481E-BE22-04FDE38E507FQ36876853-E6C861C6-AB33-42BF-94F3-4F8DDD785880Q37079916-E11DAD46-D4E3-4390-B05D-524E04B22B5BQ37263146-462D7F9E-667E-441D-86FA-219D3FC5E0A8Q37323819-DC1B2001-5C7E-4A39-A6AA-ED11721E111FQ37359503-189AD474-1E22-439D-A8F6-A03F5F615797
P2860
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Thalidomide produces transfusi ...... ith myelodysplastic syndromes.
@en
Thalidomide produces transfusi ...... ith myelodysplastic syndromes.
@nl
type
label
Thalidomide produces transfusi ...... ith myelodysplastic syndromes.
@en
Thalidomide produces transfusi ...... ith myelodysplastic syndromes.
@nl
prefLabel
Thalidomide produces transfusi ...... ith myelodysplastic syndromes.
@en
Thalidomide produces transfusi ...... ith myelodysplastic syndromes.
@nl
P2093
P356
P1433
P1476
Thalidomide produces transfusi ...... with myelodysplastic syndromes
@en
P2093
C Goldberg
F Nascimben
M du Randt
P304
P356
10.1182/BLOOD.V98.4.958
P407
P577
2001-08-01T00:00:00Z